Wednesday August 23rd 2017

Tolerogenic dendritic cells produced by Lentiviral‐mediated CD40‐ and IL‐23p19‐specific shRNA can ameliorate experimental autoimmune…

In conclusion, simultaneous knock down of CD40 and IL‐23 production by BMDCs may represent a promising therapeutic tool for the treatment of IL‐17‐dependent autoimmune diseases, including multiple sclerosis. (Source: Clinical and Experimental Immunology)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Read original article – 

Tolerogenic dendritic cells produced by Lentiviral‐mediated CD40‐ and IL‐23p19‐specific shRNA can ameliorate experimental autoimmune…

Previous Topic:

Leave a Comment

More from category

Novartis launches MS study using data collected from smartphones
Novartis launches MS study using data collected from smartphones

Novartis (NYSE:NVS) said today that it is launching a research study to better understand the daily challenges facing [Read More]

McDonald criteria: MS diagnosis guidelines
McDonald criteria: MS diagnosis guidelines

Learn about the McDonald criteria. What is dissemination in space, what is dissemination in time, and what additional [Read More]

Multiple sclerosis: Are we close to a cure?
Multiple sclerosis: Are we close to a cure?

Read this article: Multiple sclerosis: Are we close to a cure? [Read More]

Medical News Today: McDonald criteria: MS diagnosis guidelines
Medical News Today: McDonald criteria: MS diagnosis guidelines

Learn about the McDonald criteria. What is dissemination in space, what is dissemination in time, and what additional [Read More]

Medical News Today: Multiple sclerosis: Are we close to a cure?
Medical News Today: Multiple sclerosis: Are we close to a cure?

Discoveries and breakthroughs in multiple sclerosis research are building momentum, but just how close are we to [Read More]